VERU News and Press, Veru Inc. From 01/10/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: MEE KO DONG / Shutterstock.com One of last year’s surprise hits in the biotech sphere, Veru (NASDAQ: VERU ) is making headlines once again today. Currently, VERU stock is up 8%. Known for its Covid-19 the...

MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease v...

Veru (NASDAQ: VERU) rose in popularity in 2022, not due to its core business but the hype and excitement surrounding its COVID-19 drug, sabizabulin. And although the stock has been falling in recent months, that's after it experienced a significant rise in value. Below, I'll look at how muc...

Boston, Massachusetts--(Newsfile Corp. - December 20, 2022) - Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Veru Inc. (NASDAQ: VERU) and certain of its executives, for s...

New York, New York--(Newsfile Corp. - December 9, 2022) - Levi & Korsinsky, LLP notifies investors in Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) of a class action securities lawsuit. The lawsuit on behalf of Veru investors has been commenced in the the United States District Court ...

Summary Veru’s investment case is highly geared to growth opportunities, especially related to Covid-19 treatment. Veru recently suffered a setback regarding the approval of sabizabulin in the U.S., which is likely to lead to further Stage 3 trials. Veru's valuation remains h...

U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for emergency use in EU member states Sabizabulin also under review for potential emergenc...

Biotech company Veru (NASDAQ: VERU) aims to make products to treat cancer and infectious diseases. Today, however, its revenue comes primarily from its FC2 Female Condom. But that's not what has been grabbing investors' attention this year. Instead, it has been the company's potential COV...

MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Monday, December 5, 2...

After Veru (NASDAQ: VERU) got a thumbs-down from a nonbinding advisory committee at the Food and Drug Administration (FDA) on Nov. 9 regarding its drug sabizabulin for the treatment of severe COVID-19, shares of the company fell by more than 60%, and recovery is nowhere in sight. ...